- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02255188
Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning
Evaluate Hemocompatibility Vascular Prosthesis to Prevent Its Thrombosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To test the influence of the prostheses to hemostasis blood will be pumped through the vascular prosthesis or control silicone tube (both with identical inner diameter 1,7 mm) during 20 minutes at a linear velocity 10 cm/sec (corresponding to 18 ml/min). The tested prostheses (or control tubes) will be installed between two syringes with blood installed in the UTPS-1 instrument providing synchronical movement of pistons of both syringes. Installing UTPS-1 was designed and manufactured at the Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences consists of a mechanical pushers, equipped with clamps for syringes and pistons, stepper motor, electronic control unit and power supply.
UTPS-1 and polypropylene non-pyrogenic syringes filled with blood without any bulbs of air provides absence of contacts with air, pyrogens and minimize lysis of blood cells. UTPS-1 has no analogues, and does not require licensure, metrological control or obtaining of any other permits.
After pumping the blood will be separated into plasma and cell fraction according to standard laboratory methods. Primary blood (before any treatment), blood after pumping through silicon tube (control), and vascular prosthesis will be tested for hemostatic parameters.
Notification of basic and additional parameters being studied, which will be
evaluated in the study:
- The initial parameters of blood hemostasis will be evaluated (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio [INR], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), free hemoglobin and P- selectin concentrations).
- To evaluate the influence of the prosthesis to circulating blood the same hemostasis characteristics wiil be evaluated in blood after 20 min of circulation through prosthesis and silicon tube (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio [INR], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), the measurement of free hemoglobin, P- selectin).
- Microscopy: a study of adhesion of blood cells on the surface of the prosthesis
Description of Design of the Research: this will be prospective (are marked in section Detailed Description)
Monocentred research
Defined indicators for each prosthesis
1. hemostasis characteristics listed hereinabove for untreated blood (control)
2 hemostasis characteristics listed hereinabove in blood after 20 min circulation through silicone tube (control)
3 hemostasis characteristics listed hereinabove in blood after 20 min circulation through After the interaction with the experimental vascular prosthesis
Will be studied 4 types of vascular prostheses made by electrospinning
- polycaprolactone;
- polycaprolactone / gelatin/poorly permeable layer;
- polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer;
- nylon 6
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Novosibirskay obl.
-
Novosibirsk, Novosibirskay obl., Russian Federation, 630055
- popova Irina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female aged from 18 to 50 years at the date of the informed consent signing;
- Patients without atherosclerosis
- Patients without blood pathology
Exclusion Criteria:
- Patient did not sign the informed consent.
- Early postoperative period.
- Concomitant diseases such as atherosclerosis, blood pathology, venous thrombosis, malignancy, terminal cancer, infectious - inflammatory disease at the time of the study.
- Patients after implantation of a cardioverter-defibrillator; prior prosthetic heart valves or other implants, which can lead to mechanical damage to the blood cells.
- Receiving anticoagulants, antiplatelet, antibacterial drugs, NSAIDs.
- Myocardial infarction less than 3 months ago.
- Irreversible failure of major organs with an expected survival time of less than 1 year
- Pregnancy, lactation.
- Age above 50 years.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Graft type - PCL
PCL - polycaprolactone
|
30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent.
Blood sampling is carried out from an arm vein.
All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
|
Graft type - PCL/ gelatin
polycaprolactone/ gelatin/poorly permeable layer;
|
30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent.
Blood sampling is carried out from an arm vein.
All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
|
Graft type - PLGA/PCL/gelatin
PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
|
30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent.
Blood sampling is carried out from an arm vein.
All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
|
Graft type - nylon 6
|
30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent.
Blood sampling is carried out from an arm vein.
All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants (blood samples) having a higher degree of aggregation of platelets after interaction with the prosthesis, as a sign of thrombosis. (with ristomycin, adrenaline, collagen, ADP)
Time Frame: during the day
|
percentage
|
during the day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Platelet count
Time Frame: during the day
|
cells / L
|
during the day
|
Prothrombin time
Time Frame: during the day
|
seconds
|
during the day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Normalised Ratio
Time Frame: during the day
|
during the day
|
|
activated partial thromboplastin time
Time Frame: during the day
|
seconds
|
during the day
|
prothrombin Quick
Time Frame: during the day
|
during the day
|
|
thrombin time
Time Frame: during the day
|
seconds
|
during the day
|
soluble fibrin monomer complexes
Time Frame: during the day
|
0-4mg/100ml
|
during the day
|
free hemoglobin
Time Frame: during the day
|
g / l
|
during the day
|
P- selectin concentrations
Time Frame: during the day
|
ng / ml
|
during the day
|
Adhesion of blood cells on the surface of the prosthesis
Time Frame: during the day
|
microscopy
|
during the day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16.01.2014 № 2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARTERIAL OCCLUSIVE DISEASE
-
Hull University Teaching Hospitals NHS TrustWithdrawnPeripheral Arterial Occlusive DiseaseUnited Kingdom
-
Yonsei UniversityCompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
W.L.Gore & AssociatesTerminatedPeripheral Arterial Occlusive DiseaseUnited States
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, France, Germany, Italy, Switzerland, Belgium, United Kingdom
-
Ryazan State Medical UniversityRecruitingPeripheral Arterial Occlusive DiseaseRussian Federation
-
B. Braun Melsungen AGActive, not recruitingPeripheral Arterial Occlusive DiseaseGermany
-
Maquet CardiovascularCompletedPeripheral Arterial Occlusive DiseaseUnited States, Germany, Czechia
-
University Hospital Inselspital, BerneWithdrawnPeripheral Arterial Occlusive DiseaseSwitzerland
-
Flanders Medical Research ProgramAngioScore, Inc.CompletedPeripheral Arterial Occlusive DiseaseBelgium, Germany
-
Medical Scientific Fund of the Mayor of ViennaCompletedPeripheral Arterial Occlusive DiseaseAustria
Clinical Trials on blood sampling procedure
-
Central Hospital, Nancy, FranceRecruitingInflammatory Bowel Diseases | Ulcerative ColitisFrance
-
Bulent Ecevit UniversityCompleted
-
Ohio State University Comprehensive Cancer CenterFoundation MedicineCompletedStage IV Breast Cancer | Recurrent Breast Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance